

PROXY FORM

in accordance with Chapter 7 Section 54 (a) of the Swedish Companies Act

I hereby appoint the proxy stated below, or whomever he or she may appoint, to vote on my behalf for all my shares in Egetis Therapeutics AB (publ), Reg. No. 556706–6724, at the annual general meeting of Egetis Therapeutics AB (publ) on 27 April 2023.

Proxy

Name of the proxy	Personal identity number/Date of birth
Address	
Postal code and city	Telephone number

Signature by the shareholder

Name of the shareholder	Personal identity number/Date of birth/Registration number
Place and date	Telephone number
Signature*	

*If signing for a company, a clarification of signature shall be included above and an up to date certificate of registration (or the equivalent) shall be enclosed to the completed proxy form.

Please note that a shareholder shall give the company notice of attendance – as set out in the notice convening the annual general meeting – even if the shareholder intends to exercise his or her voting rights through a proxy.

The completed proxy form (with any enclosures) should be sent to Egetis Therapeutics, by post to Egetis Therapeutics, Klara Norra Kyrkogata 26, SE-111 22, Stockholm, Sweden or via e-mail to info@egetis.se, so that it has been received by Egetis Therapeutics at the latest 26 April 2023. For the avoidance of doubt, if the shareholder does *not* intend to exercise his or her voting rights through a proxy, the proxy form does not have to be submitted.

Processing of personal data

For information on how your personal data is processed, see <https://www.egetis.com> and <https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf>.